Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

26 Oct 2004

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Ovarian cancer diagnosis and treatment
Share to PI3K/AKT/mTOR signaling in cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 15505422
DOI: 10.1023/b:appt.0000045781.46314.e2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinomaPMID 15505422Read ↗

Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expressionSemantic proximity Read ↗

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian CancersSemantic proximity Read ↗

SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathwaySemantic proximity Read ↗

NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2Semantic proximity Read ↗

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Semantic proximity Read ↗

Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric CancerSemantic proximity Read ↗

CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic PredictivitySemantic proximity Read ↗

Targeting Signaling Pathways in Epithelial Ovarian CancerSemantic proximity Read ↗

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Semantic proximity Read ↗

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy optionsSemantic proximity Read ↗

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.